Rifampin
Rifadin, Rifamate, Rifater, Rimactane (rifampin) is a small molecule pharmaceutical. Rifampin was first approved as Rifamate on 1982-01-01. It is used to treat aids-related opportunistic infections, bacterial infections, bacterial meningitis, brucellosis, and haemophilus infections amongst others in the USA. It is known to target solute carrier organic anion transporter family member 1A2, solute carrier organic anion transporter family member 1B1, solute carrier organic anion transporter family member 1B3, and nuclear receptor subfamily 1 group I member 2.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Rifadin, Rimactane (generic drugs available since 1997-05-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Isoniazid
+
Pyrazinamide
+
Rifampin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RIFATER | Sanofi | N-050705 DISCN | 1994-05-31 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| rifadin iv novaplus | New Drug Application | 2023-03-06 |
| rifampin | ANDA | 2023-06-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| aids-related opportunistic infections | — | D017088 | — |
| bacterial infections | — | D001424 | A49 |
| bacterial meningitis | EFO_1000831 | D016920 | G00 |
| brucellosis | EFO_0007185 | D002006 | A23 |
| haemophilus infections | EFO_1001127 | D006192 | — |
| legionnaires' disease | EFO_0007343 | D007877 | A48.1 |
| leprosy | EFO_0001054 | D007918 | A30 |
| staphylococcal infections | — | D013203 | A49.01 |
| tuberculosis | EFO_0000774 | D014376 | A15-A19 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04A: Drugs for treatment of tuberculosis
— J04AB: Antibiotics, antitubercular
— J04AB02: Rifampicin
— J04AM: Combinations of drugs for treatment of tuberculosis
— J04AM02: Rifampicin and isoniazid
— J04AM05: Rifampicin, pyrazinamide and isoniazid
— J04AM06: Rifampicin, pyrazinamide, ethambutol and isoniazid
— J04AM07: Rifampicin, ethambutol and isoniazid
HCPCS
No data
Clinical
Clinical Trials
372 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 86 | 1 | 1 | 1 | 5 | 93 | ||
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 19 | 15 | 11 | 6 | 7 | 57 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 1 | 17 | 6 | 2 | 6 | 31 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 6 | 5 | 5 | 5 | 7 | 27 |
| Drug interactions | D004347 | 13 | 1 | — | 2 | — | 15 | ||
| Latent tuberculosis | D055985 | Z22.7 | — | 2 | 4 | 2 | — | 7 | |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 2 | 2 | — | 1 | 1 | 6 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 4 | — | — | 1 | — | 5 |
| Methicillin-resistant staphylococcus aureus | D055624 | — | 1 | — | 1 | 2 | 4 | ||
| Leprosy | D007918 | EFO_0001054 | A30 | — | 1 | 2 | 1 | — | 4 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv | D006678 | O98.7 | 2 | 2 | 1 | — | — | 5 | |
| Meningeal tuberculosis | D014390 | A17.0 | — | 4 | 1 | — | — | 4 | |
| Infections | D007239 | EFO_0000544 | 2 | — | 2 | — | — | 4 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | 2 | — | — | 3 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | 2 | — | 1 | 3 |
| Reactive arthritis | D016918 | EFO_0007460 | M02.3 | — | — | 1 | — | — | 1 |
| Sepsis | D018805 | A41.9 | — | — | 1 | — | — | 1 | |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 1 | — | — | 1 |
| Communicable diseases | D003141 | — | — | 1 | — | — | 1 | ||
| Healthcare-associated pneumonia | D000077299 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | 2 | — | — | — | 2 | |
| Chronic renal insufficiency | D051436 | N18 | 1 | 1 | — | — | — | 2 | |
| Hypercalcemia | D006934 | E83.52 | 1 | 1 | — | — | — | 2 | |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | — | — | — | 1 |
| Onchocerciasis | D009855 | EFO_0007402 | B73 | — | 1 | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | 1 | — | — | — | 1 | |
| Hypercalciuria | D053565 | R82.994 | — | 1 | — | — | — | 1 | |
| Tuberculous pericarditis | D010495 | EFO_0007426 | A18.84 | — | 1 | — | — | — | 1 |
| Buruli ulcer | D054312 | EFO_1001281 | A31.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 20 | — | — | — | — | 20 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 5 | — | — | — | — | 5 | |
| Lymphoma | D008223 | C85.9 | 5 | — | — | — | — | 5 | |
| Non-small-cell lung carcinoma | D002289 | 4 | — | — | — | — | 4 | ||
| Large-cell lymphoma anaplastic | D017728 | C84.6 | 3 | — | — | — | — | 3 | |
| Pharmacokinetics | D010599 | 3 | — | — | — | — | 3 | ||
| Biological availability | D001682 | 2 | — | — | — | — | 2 | ||
| Hematologic neoplasms | D019337 | 2 | — | — | — | — | 2 | ||
| Hodgkin disease | D006689 | C81 | 2 | — | — | — | — | 2 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | — | — | — | — | 2 |
Show 34 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acinetobacter infections | D000151 | EFO_1000792 | — | — | — | — | 1 | 1 | |
| Hidradenitis suppurativa | D017497 | L73.2 | — | — | — | — | 1 | 1 | |
| Scrub typhus | D012612 | EFO_0007480 | A75.3 | — | — | — | — | 1 | 1 |
| Body weight changes | D001836 | — | — | — | — | 1 | 1 | ||
| Motor activity | D009043 | EFO_0003940 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RIFAMPIN |
| INN | rifampicin |
| Description | Rifampicin, also known as rifampin, is an ansamycin antibiotic used to treat several types of bacterial infections, including tuberculosis (TB), Mycobacterium avium complex, leprosy, and Legionnaires’ disease. It is almost always used together with other antibiotics with two notable exceptions: when given as a "preferred treatment that is strongly recommended" for latent TB infection; and when used as post-exposure prophylaxis to prevent Haemophilus influenzae type b and meningococcal disease in people who have been exposed to those bacteria. Before treating a person for a long period of time, measurements of liver enzymes and blood counts are recommended. Rifampicin may be given either by mouth or intravenously.
|
| Classification | Small molecule |
| Drug class | tricyclic compounds; antibiotics (rifamycin derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C |
Identifiers
| PDB | — |
| CAS-ID | 13292-46-1 |
| RxCUI | 9384 |
| ChEMBL ID | CHEMBL374478 |
| ChEBI ID | 28077 |
| PubChem CID | 5381226 |
| DrugBank | DB01045 |
| UNII ID | VJT6J7R4TR (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLCO1A2
SLCO1A2
SLCO1B1
SLCO1B1
SLCO1B3
SLCO1B3
NR1I2
NR1I2
Organism
Homo sapiens
Gene name
SLCO1A2
Gene synonyms
OATP, OATP1, OATP1A2, SLC21A3
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 1A2
Protein synonyms
OATP-1, OATP-A, organic anion transporting polypeptide A, Organic anion-transporting polypeptide 1, Sodium-independent organic anion transporter, solute carrier family 21 (organic anion transporter), member 3, Solute carrier family 21 member 3
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 81,053 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,773 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more